touchPODCAST

Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease - touchRESPIRATORY

touchCLINICAL PERSPECTIVES for touchRESPIRATORY

Join Dr Helena Yu, course director, as she discusses the unmet needs and research opportunities in metastatic EGFR-mutant and wildtype NSCLC. By exploring key clinical trial data alongside real-world patient cases, healthcare providers will gain valuable insights into how to effectively implement these findings in clinical practice. In addition, the clinical experts highlight the critical role of biomarker testing in NSCLC for personalizing treatment plans and discuss the importance of patient support in navigating the NSCLC treatment journey.

Course director

Dr Helena Yu, Memorial Sloan Kettering Cancer Center New York, NY, USA

 

The clinical experts

Dr Aaron Lisberg, University of California Los Angeles (UCLA), Los Angeles, CA, USA

Dr Antonio Passaro, European Institute of Oncology, Milan, Italy

Dr Sara Pilotto, University of Verona, Verona, Italy

Ms Jackie Fenemore, Christie NHS Foundation Trust, Manchester, UK

Prof. Egbert Smit, Leiden University Medical Center, Leiden, The Netherlands and Netherlands Cancer Institute, Amsterdam, The Netherlands

 

Modules

Module 1: EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC (timestamp: 0:00 - 32:33)

Module 2: EGFR-wildtype NSCLC: Advances in the treatment landscape (timestamp: 32:34 - 01:06:10)

Module 3: Bringing it together (timestamp: 01:06:10 - 01:43:40)

 

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

 

For further information visit our website:  

https://touchoncologyime.org/egfr-and-wildtype-late-stage-nsclc-management/

For further information visit our website:  https://touchrespiratoryime.org/egfr-and-wildtype-late-stage-nsclc-management

Perspectives on EGFR-mutant and wildtype NSCLC Tailoring treatment advances in late-stage disease - touchONCOLOGY

touchCLINICAL PERSPECTIVES for touchONCOLOGY

Join Dr Helena Yu, course director, as she discusses the unmet needs and research opportunities in metastatic EGFR-mutant and wildtype NSCLC. By exploring key clinical trial data alongside real-world patient cases, healthcare providers will gain valuable insights into how to effectively implement these findings in clinical practice. In addition, the clinical experts highlight the critical role of biomarker testing in NSCLC for personalizing treatment plans and discuss the importance of patient support in navigating the NSCLC treatment journey.

Course director

Dr Helena Yu, Memorial Sloan Kettering Cancer Center New York, NY, USA

The clinical experts

Dr Aaron Lisberg, University of California Los Angeles (UCLA), Los Angeles, CA, USA

Dr Antonio Passaro, European Institute of Oncology, Milan, Italy

Dr Sara Pilotto, University of Verona, Verona, Italy

Ms Jackie Fenemore, Christie NHS Foundation Trust, Manchester, UK

Prof. Egbert Smit, Leiden University Medical Center, Leiden, The Netherlands and Netherlands Cancer Institute, Amsterdam, The Netherlands

Modules

Module 1: EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC (timestamp: 0:00 - 32:33)

Module 2: EGFR-wildtype NSCLC: Advances in the treatment landscape (timestamp: 32:34 - 01:06:10)

Module 3: Bringing it together (timestamp: 01:06:10 - 01:43:40)

 

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

 

For further information visit our website:  
https://touchoncologyime.org/egfr-and-wildtype-late-stage-nsclc-management/

Expanding HER2 horizons: Implications for NSCLC and beyond

touchPANEL DISCUSSION for touchRESPIRATORY

Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.  

The experts

• Dr Razelle Kurzrock - Medical Oncologist, Medical College of Wisconsin, Milwaukee, WI, USA
• Dr Lyudmila Bazhenova - Medical Oncologist, UC San Diego Moores Cancer Center, San Diego, CA, USA
• Dr Ignacio Wistuba - Pathologist, MD Anderson Cancer Center, Houston, TX, USA

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME. 

For further information visit our website: https://touchrespiratoryime.org/her2_in_solid_tumours_and_nsclc/

 

Expanding HER2 horizons: Implications for NSCLC and beyond

touchPANEL DISCUSSION for touchONCOLOGY

Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.  

The experts

• Dr Razelle Kurzrock - Medical Oncologist, Medical College of Wisconsin, Milwaukee, WI, USA
• Dr Lyudmila Bazhenova - Medical Oncologist, UC San Diego Moores Cancer Center, San Diego, CA, USA
• Dr Ignacio Wistuba - Pathologist, MD Anderson Cancer Center, Houston, TX, USA

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME. 

For further information visit our website: https://touchoncologyime.org/her2_in_solid_tumours_and_nsclc/

 

Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?

touchCONGRESS for touchHAEMATOLOGY

Listen to immune thrombocytopenia (ITP) expert Dr Vickie McDonald review key data presented at the European Hematology Association (EHA) and International Society on Thrombosis and Haemostasis (ISTH) 2024 congresses on the impact and current and future management of ITP. She is joined by two additional leading ITP experts, Prof. James Bussel and Prof. Waleed Ghanima, to discuss how these data may apply in clinical practice.

Overview 

• Data reviews with Dr McDonald
• Expert panel discussions with Dr McDonald, Prof. Bussel and Prof. Ghanima on the themes below

Clinical themes

1. How does ITP impact the patient and their quality of life?
2. What are the latest data that inform the use of current treatments for chronic ITP?
3. What data are there for emerging chronic ITP treatments and what do they tell us?

The internationally renowned ITP expert faculty

• Dr Vickie McDonald: London, UK
• Prof. James Bussel: New York, NY, USA,
• Prof. Waleed Ghanima: Oslo, Norway

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Sanofi and is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: 
 https://touchhaematologyime.org/itp-eha-isth-2024/ 

Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?

touchCONGRESS for touchONCOLOGY

Listen to immune thrombocytopenia (ITP) expert Dr Vickie McDonald review key data presented at the European Hematology Association (EHA) and International Society on Thrombosis and Haemostasis (ISTH) 2024 congresses on the impact and current and future management of ITP. She is joined by two additional leading ITP experts, Prof. James Bussel and Prof. Waleed Ghanima, to discuss how these data may apply in clinical practice.

Overview 

• Data reviews with Dr McDonald
• Expert panel discussions with Dr McDonald, Prof. Bussel and Prof. Ghanima on the themes below

Clinical themes

1. How does ITP impact the patient and their quality of life?
2. What are the latest data that inform the use of current treatments for chronic ITP?
3. What data are there for emerging chronic ITP treatments and what do they tell us?

The internationally renowned ITP expert faculty

• Dr Vickie McDonald: London, UK
• Prof. James Bussel: New York, NY, USA,
• Prof. Waleed Ghanima: Oslo, Norway

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Sanofi and is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: 
 https://touchoncologyime.org/itp-eha-isth-2024/

Continuous glucose monitoring in type 2 diabetes: Overcoming barriers to optimize outcomes

touchPANEL DISCUSSION for touchENDOCRINOLOGY

Listen to a panel of experts discuss the benefits of CGM in patients with T2D, strategies to overcome the barriers to its uptake and how to best support patients in implementing CGM.

The experts

• Prof. Stewart Harris, Western University,  London, Ontario, Canada,
• Dr Anders Carlson, International Diabetes Center at Park Nicollet, Minneapolis, MN, USA,
• Prof. Shannon Idzik, University of Maryland School of Nursing, Baltimore, MD, USA
  

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Abbott Diabetes Care Inc. This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: 
www.touchENDOCRINOLOGY.com 

Personalizing care within the MDT for patients with early through to advanced RCC

touchFOCUS for touchONCOLOGY

Listen to Prof. Hans Hammers as he answers a series of questions on the application of prognostic markers and clinical data within the multidisciplinary team to personalize care for patients with early stage through to advanced and metastatic RCC. In addition, he responds to questions on the use of effective communication strategies and shared decision-making when managing diverse and/or underserved populations with RCC.

The expert

• Prof. Hans Hammers, UT Southwestern, Dallas, TX, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from MSD. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/personalizing-care-multidisciplinary-team-renal-cell-carcinoma/

Selecting ART: Working with people living with HIV to find the best regimen

touchIN CONVERSATION for touchINFECTIOUS DISEASES

Listen to a conversation between Dr Christoph Boesecke and Dr Tristan Barber, two experts on HIV practising in Germany and the UK. They respond to questions submitted by the HCP audience and provide their insights on best practices for antiretroviral therapy selection for people living with HIV.

The experts

• Dr Christoph Boesecke – University of Bonn, Bonn, Germany
• Dr Tristan Barber – Royal Free London NHS Foundation Trust, London, UK

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical educational grant from ViiV Healthcare. This activity is provided by touchIME.

For further information visit our website:

https://touchinfectiousdiseases.com/education/hiv-art-selection-shared-decision-making/

 

 

 

Thyroid eye disease: An evolving continuum of care

touchPANEL DISCUSSION for touchOPHTHALMOLOGY

Listen to a panel of leading experts discuss thyroid eye disease, including the underlying mechanisms, risk factors, symptomatology and burden of disease in affected patients, as well as the process for screening and diagnosing the disease.

The experts

• Dr Andrea Kossler, Stanford University School of Medicine, Palo Alto, CA, USA
• Dr Mario Salvi, University of Milan, Milan, Italy
• Dr Edsel Ing, University of Alberta, Edmonton and University of Toronto, Ontario, Canada

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Horizon Therapeutics and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit:

https://touchophthalmologyime.org/thyroid-eye-disease-an-evolving-continuum-of-care/